Our Pipeline
Our Pipeline
Currently in various stages of development and growth, our product portfolio is built upon novel drugs that have the potential to address worldwide unmet medical demands.
Human Health Product Portfolio
Swipe horizontally to view the full table
| INDICATION |
RESPONSIBLE ENTITY |
DEVELOPMENT STAGE |
GEOGRAPHIC FOCUS OF CLINICAL STUDIES |
||||
|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Commercialized (US) |
|||
Crofelemer (tablet formulation) - Licensed to Future Pak in US in January 2026
|
|||||||
| Noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy | Commercialized in the US by Future Pak affiliate Theratechnologies Inc. under license from Napo Pharmaceuticals | US | |||||
| Ultrarare pediatric microvillus inclusion disease (MVID) |
|
Crofelemer has orphan-drug designation in the US and EU for MVID |
EU, US & Middle East |
||||
| Rare disease: Adult short bowel syndrome with intestinal failure (SBS-IF) |
|
Crofelemer has orphan-drug designation in the US and EU for SBS | EU | ||||
